Odyssey Health, Inc.

Odyssey Health, Inc.

Overview

• Nevada corporation, formed March 2014.

• Principal executive offices: 2300 West Sahara Avenue, Suite 800 - #4012, Las Vegas, NV 89102.

• IPO registration statement effective July 2015; shares trade on OTC Markets (OTCID). Public market for the stock is very limited.

• The company uses the names Odyssey, ODYY, the Company, our Company, we, us, and our interchangeably.

• Mission: create or acquire assets, intellectual property, and technologies with clinical utility to meet unmet medical needs.

• Business model: develop or acquire medical products, engage third parties for development, conduct clinical trials, and manufacture under FDA regulations.

• Current product candidates: CardioMap (heart monitoring) and Save-A-Life (SAL, choking rescue device).

• Strategy: acquire or identify additional technologies, license or directly market products, and build domestic and international distribution channels.

Product candidates and development status

• CardioMap

  • Description: heart monitoring and screening device using a Dispersion Mapping method in ECG analysis to produce 3-D visualization for diagnosis; intended for professional, remote, and at-home use.
  • Intellectual property: exclusive U.S. patent rights (U.S. patent 7,519,416 B2).
  • Status: working model exists. Plan to pursue clinical trials and a 510(k) FDA submission when funded.
  • Development plan: Concept → Engineering → Model → Prototype → Clinical Trial → FDA Submission.
  • Current funding: program not funded in the near term; development suspended in the near term.

• Save-A-Life (SAL)

  • Description: choking rescue device that uses a vacuum-based mechanism with a replaceable mouthpiece to remove a lodged mass from the airway.
  • Intellectual property: patents RE45,535 E and 8,454,624 B2.
  • Status: in development; FDA clearance or approval has not been obtained.
  • Development plan: Concept → Engineering → Model → Prototype → Clinical Trial → FDA Submission.
  • Current funding: SAL development is prioritized over CardioMap.

Competition

• SAL competitors (or comparable devices): Dechoker, LifeVac, Act+Fast Heimlich training devices and related products.
• CardioMap competitive landscape: positioned to offer dispersion-mapping capabilities not present in typical EKG devices; typical competitors provide standard EKG readouts (examples include CardioResting, Welch Allyn PC-based EKG, QardioCore).

Regulatory environment

• FDA clearance or approval is required to market CardioMap and SAL in the U.S.; none obtained.
• Foreign sales require country-specific clearances or approvals.
• Regulatory processes are costly and time-consuming and can affect development timelines and commercialization plans.

Employees and facilities

• Two employees.
• No owned real property; the company leases minimal office space at the principal address.

Financial position and revenue

• The company has not generated revenue or profit since inception.
• Net loss for the fiscal year ended July 31, 2026: $5,729,693.
• Accumulated deficit as of July 31, 2026: $68,475,530.
• As of July 31, 2026:
  • Current liabilities: $12,277,546
  • Current assets: $147,859
  • Working capital deficit: $12,129,687
• Independent auditors issued an explanatory paragraph expressing substantial doubt about the company’s ability to continue as a going concern.
• Continuing operations depend on obtaining additional financing; there are no commitments for such financing.
• Historically financed through secured and unsecured convertible debt, equity issuances, and related-party loans. Future equity or convertible issuances may dilute existing stockholders. The company is actively seeking financing and strategic partnerships.

Convertible notes and indebtedness

• Aggregate principal outstanding as of July 31, 2026: $4,876,282 (plus accrued interest), with about $3,835,282 owed to Mast Hill Fund, L.P.
• Mast Hill note (August 2025) matured August 27, 2026 and was not repaid.
• Reserved amount for conversion of notes into common stock was not sufficient to cover all potential conversions.
• Global Amendment dated October 23, 2026 extended maturity dates to January 31, 2027 and provided one-time waivers of certain events of default through that date; waivers are limited to specific events and do not apply to other defaults or defaults arising after October 23, 2026.
• If defaults are triggered and not waived, noteholders may accelerate amounts due and pursue remedies, including bankruptcy or restructuring, which could result in dilution or loss to stockholders.
• As of October 27, 2026: 110,218,663 shares of common stock outstanding and 500,000,000 shares authorized.

Intellectual property and litigation risk

• IP protection through patents, trademarks, trade secrets, and confidentiality agreements.
• No active IP litigation disclosed.
• Potential future litigation risk exists given the nature of the business.

Consolidated business summary

• Odyssey Health, Inc. is a development-stage medical technology company focused on acquiring or developing technologies with clinical utility, currently centered on CardioMap (heart monitoring and dispersion-mapping) and Save-A-Life (vacuum-based choking rescue).
• CardioMap development is suspended in the near term due to funding constraints; SAL development is prioritized.
• The company operates with a very small staff and minimal office space and depends on external financing to fund operations and product development.
• Capital structure includes outstanding convertible debt and a large number of authorized but unissued shares, creating potential dilution risk for shareholders.

Notes

• Figures reflect company disclosures as of July 31, 2026, with subsequent updates through October 2026 related to the Global Amendment and outstanding shares.